The following is the Top ten pharmaceutical companies and drugs with the highest sales in the world in 2021 recommended by recordtrend.com. And this article belongs to the classification: Medical health.
Although Pfizer has created a gap of more than $16billion with its closest competitor abbvie, it is expected that the sales of comirnaty and other vaccines will decline sharply in the next few years. At present, most western countries have been vaccinated with two or even three doses of vaccine, while the main prevalent Omicron mutant is less pathogenic, and the demand for the fourth vaccination is also declining.
Although there is no new crown related product, due to the outstanding performance of the money spinner Humira, the BTK inhibitor imbruvica, and the approved listing of the new psoriasis drug IL-23 inhibitor skyrizi, EBV rose one place to the second place in 2021. However, as the biosimilar drug of the former king adalimumab will enter the market in 2023, the company’s ranking will inevitably decline.
The rapid growth of Pfizer and Alberta has directly affected the rankings of Novartis and Roche, which have dropped two places and three places respectively compared with the rankings in 2020. Neither of the two companies has any star products related to the new crown. At the same time, the epidemic has caused the sales of the large single product ocrevus in Roche’s central nervous system to fall short of expectations. At the same time, another popular drug Avastin has also been affected by biosimilar drugs. On the other hand, Novartis sold its 33% stake in Roche last year and obtained US $20.7 billion, which will support its rapid expansion of pipelines through acquisition.
Under normal circumstances, Merck & Co.’s ranking may rise due to the continued strong sales of pabolizumab K (keytruda), but because of the excellent performance of the two new crown vaccines, K only ranked fourth in the sales list in 2021. MSD ranked seventh in the revenue list. According to the forecast, the sales of keytruda, a PD-1 inhibitor, may reach 20billion US dollars this year. Meanwhile, with the weakening demand for Xinguan vaccine, K drug is expected to win the title of the best-selling drug of the year by virtue of the sales of 21.6 billion US dollars in 2023.
AstraZeneca entered the top 10 in 2021 due to the strong growth of cancer drugs and the acquisition of alexion company with us $39billion last year, which brought it a heavy bomb in the field of several rare diseases. The future growth will come from enhertu (ds-8201) jointly developed with Daiichi Sankyo, an innovative ADC drug for her2+ breast cancer, which has shown impressive efficacy.
Although Bristol Myers Squibb (BMS) has three of the top 10 best-selling drugs, the company is not at the top of the list, only ranking sixth. In addition, as the patent of Revlimid (lenalidomide), a multiple myeloma blockbuster from celgene, is about to expire, the sales volume is expected to decline this year. Eliquis, an anticoagulant, entered the $10 billion club for the first time, ranking sixth after lenalidomide. Opdivo, a PD-1 inhibitor of BMS, returned to the growth curve in 2021, ranking ninth in the list of the best-selling drugs with a sales of US $7.6 billion. A number of preoperative and postoperative indications (adjuvant therapy for bladder cancer, neoadjuvant therapy for lung cancer, adjuvant therapy for esophageal cancer and GEJ, and adjuvant therapy for melanoma) will help drug o narrow the gap with drug K.
Gilead is gratified by the strong sales of biktarvy (bicetavir / ntriptabine / propofol tenofovir), a combination therapy for HIV, but the sales of its new crown antiviral drug, veklury, fell sharply, reaching US $5.6 billion in 2021. People are worried about its excessive dependence on drugs in the field of infectious diseases. Biktarvy accounts for 1/3 of the total sales of Gilead In 2021. Therefore, Gilead is under increasing pressure from other pipelines. In particular, since 2017, the company has spent more than $38billion to acquire companies such as immunologics and kite pharma.
GlaxoSmithKline (GSK) is no stranger to investors. GlaxoSmithKline is facing a crucial year as no drugs are shortlisted in the top 10 best-selling list and ranked bottom in the top 10 pharmaceutical companies’ revenue list. The delay of its new crown vaccine with Sanofi led the two companies to miss the wealth enjoyed by Pfizer and Moderna, while Sanofi stagnated in the eighth place. After the split of haleon, the consumer health department, in July, the performance of GlaxoSmithKline’s pharmaceutical department will receive closer attention.
reference material: https://doi.org/10.1038/d41573-022-00047-9
From: Lanting will read more: DPI: AI for drug discovery in 2020 Overview of biomarker development and drug R & D doctor clove: 2021 Chinese doctor insight report (with download) medical equipment collection: 2019 Blue Book of Chinese medical devices (with download) SVB: 2021 Silicon Valley Bank’s health care investment and exit trend report 36 krypton Research Institute: China’s new crown vaccine industry insight in 2022 morningconsult: 1/3 of Americans have tried cannabis diphenol products American Heart Association: only 40% of pregnant women in the United States have good heart health before pregnancy Lancet: an article to understand the present and future of radiotherapy SPD Silicon Valley Bank: 2020 Chinese medicine health care industry investment and exit Trend Report (download attached) aimsen:2020 online medical industry talent development report (download attached) love analysis: China’s Internet hospital industry trend report in 2020 (download attached) information: medical device / diagnostic industry transaction statistics in the first quarter of 2020 artery Orange: global medical and health industry capital report in the first half of 2020 (download attached) iResearch: 2020 white paper on China’s household medical and health service consumption (download attached) Accenture’s research on cancer The survey of patients with three types of heart and immune diseases shows that 80% of the Chinese patients interviewed have started to receive Internet diagnosis and treatment
If you want to get the full report, you can contact us by leaving us the comment. If you think the information here might be helpful to others, please actively share it. If you want others to see your attitude towards this report, please actively comment and discuss it. Please stay tuned to us, we will keep updating as much as possible to record future development trends.
RecordTrend.com is a website that focuses on future technologies, markets and user trends. We are responsible for collecting the latest research data, authority data, industry research and analysis reports. We are committed to becoming a data and report sharing platform for professionals and decision makers. We look forward to working with you to record the development trends of today’s economy, technology, industrial chain and business model.Welcome to follow, comment and bookmark us, and hope to share the future with you, and look forward to your success with our help.
-
-
-
-
